Resolving a three-year-long court fight, the U.S. Supreme Court June 12 ruled that Sandoz can commence marketing of its biosimilar white blood cell growth factor immediately after getting FDA approval.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
